Veru (VERU) Stock Overview
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VERU Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeVeru Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.22 |
| 52 Week High | US$7.40 |
| 52 Week Low | US$2.06 |
| Beta | -1.17 |
| 1 Month Change | -7.50% |
| 3 Month Change | -0.89% |
| 1 Year Change | -55.72% |
| 3 Year Change | -85.10% |
| 5 Year Change | -96.93% |
| Change since IPO | -96.65% |
Recent News & Updates
Recent updates
Veru Inc.'s (NASDAQ:VERU) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...
Aging Trends And FDA Clarity Will Unlock Opportunity
Veru’s future P/E has increased and its net profit margin has declined, indicating deteriorating profitability expectations, but analysts maintain their fair value estimate unchanged at $25.00. What's in the News Veru announced a novel modified release oral formulation for enobosarm in chronic weight loss, achieving target pharmacokinetics and leveraging proprietary delivery technology with positive Phase 2b efficacy and safety data.Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge
NasdaqCM:VERU 1 Year Share Price vs Fair Value Explore Veru's Fair Values from the Community and select yours Veru Inc...Veru Inc.'s (NASDAQ:VERU) 28% Share Price Surge Not Quite Adding Up
Veru Inc. ( NASDAQ:VERU ) shareholders have had their patience rewarded with a 28% share price jump in the last month...Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Summary Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts. Veru's strong Phase 2b data and market potential suggest a substantial upside despite notable risks, making it a classic speculative investment. While current valuation assigns a minimal probability of success, a positive launch could yield peak sales in the billions. Read the full article on Seeking Alpha
Enobosarm Phase III And Sabizabulin Tests Will Yield Mixed Prospects
Successful clinical trials indicate potential for regulatory approval and commercialization, enhancing future revenue and earnings.Veru Inc.'s (NASDAQ:VERU) 27% Price Boost Is Out Of Tune With Revenues
Those holding Veru Inc. ( NASDAQ:VERU ) shares would be relieved that the share price has rebounded 27% in the last...Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Veru (NASDAQ:VERU) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You
Veru Inc. ( NASDAQ:VERU ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Veru Inc. ( NASDAQ:VERU ) share price has softened a substantial 35% over the previous 30 days, handing back much...The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Veru Inc. ( NASDAQ:VERU ) shareholders won't be pleased to see that the share price has had a very rough month...Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
The latest analyst coverage could presage a bad day for Veru Inc. ( NASDAQ:VERU ), with the analysts making...Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the Veru Inc. ( NASDAQ:VERU ) share price has dived 38% in the last thirty days...Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
How far off is Veru Inc. ( NASDAQ:VERU ) from its intrinsic value? Using the most recent financial data, we'll take a...Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Shareholder Returns
| VERU | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.9% | 6.2% | 3.2% |
| 1Y | -55.7% | 33.4% | 31.0% |
Return vs Industry: VERU underperformed the US Pharmaceuticals industry which returned 34.5% over the past year.
Return vs Market: VERU underperformed the US Market which returned 29.8% over the past year.
Price Volatility
| VERU volatility | |
|---|---|
| VERU Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VERU has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VERU's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 20 | Mitch Steiner | verupharma.com |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.
Veru Inc. Fundamentals Summary
| VERU fundamental statistics | |
|---|---|
| Market cap | US$35.47m |
| Earnings (TTM) | -US$19.20m |
| Revenue (TTM) | n/a |
Is VERU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERU income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.20m |
| Earnings | -US$19.20m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VERU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 06:08 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veru Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Yuchen Ding | Jefferies LLC |
| Leland Gershell | Oppenheimer & Co. Inc. |